A Phase II/III Trial of Lopinavir/Ritonavir Dosed According to the WHO Pediatric Weight Band Dosing Guidelines.

Trial Profile

A Phase II/III Trial of Lopinavir/Ritonavir Dosed According to the WHO Pediatric Weight Band Dosing Guidelines.

Completed
Phase of Trial: Phase II/III

Latest Information Update: 28 Oct 2017

At a glance

  • Drugs Lopinavir/ritonavir (Primary) ; Nucleoside reverse transcriptase inhibitors
  • Indications HIV-1 infections
  • Focus Adverse reactions; Pharmacokinetics
  • Acronyms IMPAACT-P1083
  • Most Recent Events

    • 28 Oct 2017 Primary endpoint (Area under curve (AUC) for lopinavir) has been met, according to the results published in the Pediatric Infectious Disease Journal
    • 28 Oct 2017 Results published in the Pediatric Infectious Disease Journal
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top